Tempus AI just went shopping in the cancer genomics aisle, picking up Personalis for a deal worth somewhere between $1.5 and $1.9 billion depending on which press release you trust. Precision oncology is having a very expensive week.

One Data Platform to Rule the Tumor Board

Tempus AI announced a definitive agreement to acquire Personalis, a genomics company specializing in molecular residual disease (MRD) testing — the science of hunting for trace cancer DNA left behind after treatment. Personalis shareholders get $16.25 per share, a roughly 6% premium to Friday's closing price, paid mostly in Tempus stock with an option for up to 50% cash.

The deal is structured as a stock-for-stock merger with a capped exchange ratio, and it's expected to close in late 2026 or early 2027 pending regulatory sign-off. It slots Personalis's MRD testing directly into Tempus's existing AI-driven precision oncology platform.

Why Buy the Lab When You Can Buy the Data

Tempus has built its business on the idea that AI models are only as good as the biological data feeding them, and MRD testing generates exactly the kind of longitudinal, high-stakes data that's brutally hard to replicate from scratch. Buying Personalis is a data-acquisition move dressed up as a diagnostics acquisition.

It also fits a pattern playing out across AI-enabled healthcare right now: model architecture stopped being the moat a while ago, and proprietary clinical data became the thing worth paying nine figures for. Expect more of this, not less.

In an industry racing to out-model each other, Tempus just bet that the winning move is owning more of the biology, not just more of the compute.

Source: Tempus AI